Member Info for Nolupus

Still falling ?

Bottomed out ?

Well, Just keep waiting for someone to spend circa 50 million ...

Retour du renard,

Who says that Incanthera have no plans for their IPO ??

Last news was that they were actively planning on an IPO...

but even with that Cash ...Imm would still have to find many more millions to fund another P3.

@Trek

" The Co is fully financed for another P3 merry-go-round! " ???

Have you seen the Cash balance ?

The company is a long way off being able to finance a new P3 imo ....

GSK gets approval....

https://www.gsk.com/en-gb/media/press-releases/gsk-receives-positive-chmp-opinion-for-intravenous-benlysta-in-children-with-lupus-aged-five-years-and-above/

Halfbutt,

One day, you will get it right ...

Bought back in, and staying in :-)

Maybe, but they have been "talking to potentiel partners" for over a year already...

Not in my opinion, easyp

The difference in standard of care treatments between the States and Mauritius is a more likely explanation, imv

But everyone to their own views

Think Again, Halfbutt :-))

Well, where do we go from here ?

A new P3 trial for Lupuzor seems to be on the cards, but funding needs to be found and then one would have to wait 2-3 years for the results.

Going to be a long wait, imo

A read
https://www.evaluate.com/vantage/articles/news/trial-results/second-time-lucky-astra-lupus

Hard question to answer, Gareth...

Any possible good news will come from Ureka or Nucant imo, but everyone to their own opinion

IMM will also need to get back their 2 million investment into Incanthera ....

AstraZeneca meets primary endpoint in Lupus trial --- Tulip 2

https://www.astrazeneca.com/media-centre/press-releases/2019/anifrolumab-phase-iii-trial-meets-primary-endpoint-in-systemic-lupus-erythematosus-29082019.html

Let's not forget ....

https://www.nature.com/articles/s41467-019-08793-y

The chances of IMM going bust within the timeframe are next to nil..imo

so no risk, imv

Gareth3672,

Landstead, once again is in a win/win situation if you read the RNS..

Commission and set up costs ....
The Company will pay Lanstead's legal costs incurred in the Subscription and in entering into the Sharing Agreement and, in addition, has agreed to issue to Lanstead 1,328,290 Value Payment Shares.

The risk for landstead ?? please let me know if you can find one :-)

if on a monthly settlement date the calculated Measured Price exceeds the Benchmark Price by 10 per cent., the settlement on that monthly settlement date will be 110 per cent. of the amount due from Lanstead on that date. If on the monthly settlement date the calculated Measured Price is below the Benchmark Price by 10 per cent., the settlement on the monthly settlement date will be 90 per cent. of the amount due on that date. Each settlement as so calculated will be in final settlement of Lanstead's obligation on that settlement date.

Trek,
thanks for the link...

Unfortunately for patients and families awaiting a cure or even just a better life, this company raised hope far and above acceptable levels, imv
The science needed to be proved before the hype, Ethics and respect for patients should come first in this industry imo but business is business for some people !
We all would like to see progress in treating this disease